SinoMab BioScience Limited’s IPO On The Hong Kong Stock Exchange

Herbert Smith Freehills has advised the joint sponsors of the IPO of SinoMab BioScience Limited on the Main Board of the Stock Exchange of Hong Kong.

The IPO raised approximately HK$1.29 billion.

China International Capital Corporation Hong Kong Securities Limited and Orient Capital (Hong Kong) were the joint sponsors of the listing.

SinoMab BioScience Limited is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases.

The team advising the joint sponsors of SinoMab BioScience Limited was led by partner Jason Sung (Picture), assisted by senior associates George Wu and Lawrence Cheng and associates Kris Cheung and Karen Liu. Additional support provided by Singapore partner Siddhartha Sivaramakrishnan and associate Sophia Tan.

Involved fees earner: Lawrence Cheng – Herbert Smith Freehills; Kris Cheung – Herbert Smith Freehills; Karen Liu – Herbert Smith Freehills; Siddhartha Sivaramakrishnan – Herbert Smith Freehills; Jason Sung – Herbert Smith Freehills; Sophia Tan – Herbert Smith Freehills; George Wu – Herbert Smith Freehills;

Law Firms: Herbert Smith Freehills;

Clients: SinoMab BioScience Limited;

Author: Michael Patrini